I’ve known @iancassel for 15 years. I’ve learned so much from him and few people have done more to champion the microcap space.
His new book, Stock Picker, is a great read. Fast-paced, personal, & full of lessons for all investors. Highly recommend it.
a.co/d/010sPHa8
$BBXIA. Updating this one again.
O/S declined 15% in '21 from 19.3M to 16.3M. Buybacks will continue as co announced a new 15M share repurchase in January.
Book value is $20.79; +~30% YoY.
Share price is more than 50% below BV @ $9.78.
$BBXIA. Co just repurchased 1.3M shares from a shareholder, likely Angelo Gordon @$11.10/share. Book value increases to ~$20.45. Quite the year for this company buying back its' own stock and yet it is still trading nearly 50% below book value.
$VNRX signed a 28M agreement w $HSKA this week to expand cancer detection in dogs. Per CC, co negotiating w 2 other companies as well.
Global opp, but U.S. TAM likely larger than one would think. 77M dogs. 20M>7 years old. 15M visit a vet annually.
youtube.com/watch?v=kzIM1Gfk…
$SMTI Revs grew 55% to 24M during '21. December was a record month despite Covid. Cellerate sold into 471 hospitals; 1100 approved. Telemed pilot expanded to 6 sites. 30 RSM's now.
Hospital approvals remain a key forward indicator. New product launches will add to growth in '22
$SMTI. Earnings takeaways.
1️⃣2Q revenue +112% YoY
2️⃣Cellerate sold into ONLY 300 hospitals but over 900 now APPROVED
3️⃣Regional Sales Managers increased 45% in the Q; 18 to 26.
4️⃣ Key forward indicators = Hospital approvals & RSM’s both strongly pointing higher
$NEPH 4Q CC highlights
HDF on schedule for mid year 510k FDA clearance
New filter win w/national QSR chain; thousand + locations; $250k revs '22
Strategic supplier to two new dialysis cos; $500k revs '22
Commercial discussions w/3 leading firms re water pathogen distribution
6
$BBXIA. Co just repurchased 1.3M shares from a shareholder, likely Angelo Gordon @$11.10/share. Book value increases to ~$20.45. Quite the year for this company buying back its' own stock and yet it is still trading nearly 50% below book value.
$BBXIA +226% in nearly 12 months. Co announced they expanded their buyback by $10M tonight. Valuation still trades at a big discount to book value; $18+/share vs. current price of $8.66. Active buyback + potential uplist are catalysts for higher price.
otcmarkets.com/stock/BBXIA/n…
$TCI. Catalyst playing out as expected. Filing over the weekend disclosed the JV is being put up for sale. Bankers expected by year end. Not only is book value significantly higher, but shares are currently trading 10%+ below the recent take out offer.
$TCI. +50% in ~12 months. Company received a $44 takeout offer last night. Book value is likely much higher than that. Catalyst around monetizing the Macquarie JV remains mid-November. Several different scenarios for a higher price in the next few months. finance.yahoo.com/news/brixt…
1
9
Thanks @CoInvestorClub1. Honored to make the list.
This week we featured @neilcataldi as a top 50 Microcap Investor. Check out our newsletter ⬇️
coinvestorclub.substack.com/…
$TCI. +50% in ~12 months. Company received a $44 takeout offer last night. Book value is likely much higher than that. Catalyst around monetizing the Macquarie JV remains mid-November. Several different scenarios for a higher price in the next few months. finance.yahoo.com/news/brixt…
$TCI. Normally a very quiet stock, traded 13x avg volume. JV w/Macquarie is multi-family real estate; see link. Catalyst. November 19, terms of JV change allowing either TCI or Macquarie to monetize without mutual consent. JV alone is likely worth $800M+. abodeproperties.com/current-…
$BBXIA +226% in nearly 12 months. Co announced they expanded their buyback by $10M tonight. Valuation still trades at a big discount to book value; $18+/share vs. current price of $8.66. Active buyback + potential uplist are catalysts for higher price.
otcmarkets.com/stock/BBXIA/n…
$BBXIA +150% in 8 months. Announced tender this week. PPS trading above tender price today at $6.78. Still big discount to book value which will increase to ~$18.75/share post tender.
Top Idea 🔥🔥
Cogstate ($CGS.ASX $COGZF) 🧠
Cogstate is the best public way to invest in the upcoming Alzheimer’s R&D and drug commercialization boom that is just beginning.
This is one of the best setups I’ve come across recently. No one is following this story. 1/10 👇👇
Cogstate update. $COGZF. Co announced tonight $35M in bookings since July 1. Big #. Decentralized trials is a key theme to watch going forward. asx.com.au/asxpdf/20210824/p…
The latest blog post from Bill Gates went live featuring Cogstate tonight. $CGS $COGZF. gatesnotes.com/Health/New-br…
Short list of names in consideration for the pitch from sub $50M market cap to $250M. Which should I choose? $ATGN $SMTI $VTSI $NEPH $MILC $TCI
Replying to @iancassel
Some of our top @MicroCapClub members will be pitching their favorite microcap ideas including:
@AltaFoxCapital
@1MainCapital
@michael2017l
@veritasvatillum
@AKWilk
@majgeoinvesting
@SlingshotCap
@NimbleOpinions
@neilcataldi
@chcap2016
$SMTI. Earnings takeaways.
1️⃣2Q revenue +112% YoY
2️⃣Cellerate sold into ONLY 300 hospitals but over 900 now APPROVED
3️⃣Regional Sales Managers increased 45% in the Q; 18 to 26.
4️⃣ Key forward indicators = Hospital approvals & RSM’s both strongly pointing higher




